Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
about
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Behavioral patterns associated with chemotherapy-induced emesis: a potential signature for nausea in musk shrews.Toxicity of platinum compounds.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyAprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonEfficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.Clinical practice guidelines on antiemetics in oncology.Emerging drugs for chemotherapy-induced emesis.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantThe effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting.Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.State of the Art Antiemetic Therapy for Cancer Patients.Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy.Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.
P2860
Q34450534-379041D1-009D-4B75-8711-DB2EA8B13965Q34458672-612FCC98-74AB-4377-BE62-7EBB91855413Q34588516-54291E70-CD62-4470-9EFC-1C93311C6D40Q35114037-81B25E88-C774-471B-892D-AEA137409887Q35143947-A125BAC6-6C6D-4F67-872F-EAF838E63702Q35345557-5505AE4E-5D55-4DD9-8682-D179E1A45389Q35962019-22635AF0-369D-432C-B2B6-39D21471BDCFQ35964412-BB8D676C-61B2-483F-84DC-E89747BC0983Q35970506-CB9B638D-EC09-4024-9C2E-4FA2598FA536Q36070497-263C22B0-9158-4D76-9D53-8BA5AEE85E4AQ36222937-C70D118E-B2EE-4365-9AD8-2A37252CE134Q36276557-DBE484F1-B826-4E7F-BCED-4B82FCBF28B2Q36284018-E7BAB22E-9B82-4DFC-9D2D-C7F89D00CA22Q36334870-32310274-56CC-4D3C-A389-222B5F79E11AQ36407422-C0198542-88EC-4AD4-B705-2314FDBD6AD5Q36823546-EAF06BE4-4555-40CB-8189-F98A1E88A8EEQ36900854-5CF42021-3D62-4D0C-96BA-29C1DF0FC109Q37174198-9F8ABDFA-1E7E-4552-9B43-D5B685A50F84Q37677897-C29418EF-3C80-465A-BA52-F19D96E8A2D2Q37854702-AA929540-5143-464C-94B0-3AA7500F1394Q37902946-DE48A390-578E-4BAC-BDDF-78590FE3E9C5Q38036613-8C60B82B-B880-403F-A479-9E042504BD31Q38609969-E7CCC574-C65A-4142-BFF5-ACAB2C9EC0BCQ38676452-B1A772A0-7A3E-44B4-AD2E-789A60232B89Q40030462-A193167B-BCEE-4DC7-81AD-9F7760E243B6Q42551206-64DA0E27-C0E4-427F-B9F4-56D2726B1AFFQ44062377-AF720ABB-AC70-4CA0-A739-16ACBEDE43AFQ44571968-ACE759F8-502D-43AA-80F9-5EF82F09203CQ44770183-BA5C64DD-CCF9-49DF-B371-FAA963A499B2Q44925317-E5C7B2AA-3B77-4ADE-A48E-A899E798BF10Q44973290-E3BF1148-CEE4-47C2-9EDD-26B1D97207C2Q45077382-60A4A588-242B-4237-A325-C91CFBFF984DQ46954375-605D5496-0C55-4C76-B5D1-ED0FE628EC6DQ47636194-DAA7794F-A980-4B0F-8904-6C4D01378AC1Q50441498-F8B222F2-2320-48FD-9AB6-26A59964E492Q53828936-302BC1E9-243A-4A51-A1FC-1F837234AF75
P2860
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@en
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@nl
type
label
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@en
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@nl
prefLabel
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@en
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@nl
P2093
P1476
Prevention of cisplatin-induce ...... e or with dexamethasone alone.
@en
P2093
A D Carides
C Carracedo
J Martinez-Cedillo
J R Pereira
J Wittreich
L O Eriksson
P304
P356
10.1200/JCO.2001.19.6.1759
P407
P577
2001-03-01T00:00:00Z